Novartis

Novartis announces commencement of tender offer to acquire Tourmaline Bio

Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer ...
Novartis

Bringing breakthroughs to more patients

At Novartis, we don’t just discover life-changing medicines, we're part of a broader effort to help ensure medicines reach the people who need them most, wherever they live, because the true value of ...
Novartis

Diseases of Aging and Regenerative medicine (DARe) research at Novartis

DARe is currently investigating three fundamental processes associated with aging and age-related diseases that have potential to deliver novel therapeutic approaches. These processes are intricately ...
Novartis

Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025

Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of PluvictoTM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPC NATALEE ...
Novartis

Nurturing the next generation of scientists

Maxwell Tawanda Chirehwa, a pharmacometrician from Zimbabwe currently completing his Ph.D. in South Africa, will soon pack his bags to head home from Basel, Switzerland. He’s been there for three ...
Novartis

Career Search

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.
Novartis

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s ...
Novartis

Addressing unmet needs for inherited neuromuscular diseases

Acquisition of Kate Therapeutics enhances and strengthens Novartis strategic priorities in gene therapy and neuroscience innovation Transaction includes enabling technology platforms and therapeutic ...
Novartis

FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year

With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction 1 Leqvio provides effective and sustained LDL-C ...
Novartis

Marc’s story: Raising awareness of elevated Lp(a) in cardiovascular disease

Having elevated levels of lipoprotein (a), or Lp (a) for short, increases a person’s chances of having a cardiovascular event such as a stroke or a heart attack. It was after having two heart attacks ...
Novartis

Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure

Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease (ADPKD), a severe renal disease Lead asset for ADPKD ...
Novartis

Novartis receives complete response letter from U.S. FDA for inclisiran

The U.S. Food and Drug Administration (FDA) has not raised any concerns related to the efficacy or safety of inclisiran. The complete response letter is due to unresolved facility inspection-related ...